ArticleJMIR research protocols2025
Outcome Evaluation of a Multimodal Suicide Prevention Program Designed Through International Collaboration: Protocol for a Controlled Interrupted Time Series Study.
Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Coopération Québec-France contre la Dépression et l'Isolement (CQFD-I) initiative represents a collaborative effort between Outaouais, a region in Quebec, and Brest, a metropolitan area in France, to reduce suicide through a multimodal approach. CQFD-I integrates 5 key strategies: a web portal on depression, education of primary care physicians on depression, training for mental health professionals in suicide risk assessment and management, and standardized postcrisis outreach and outpatient monitoring protocols.
objectiveThis paper aims to evaluate the effectiveness of CQFD-I in reducing outcomes related to suicidal behavior, namely suicide mortality, hospitalizations due to suicide attempts, and emergency room visits for suicide attempts, across the implementation sites compared to control areas.
methodsThe evaluation will use a controlled, segmented interrupted time series design, spanning 3 distinct phases: preimplementation (2015 to 2020), implementation (2020 to 2022), and postimplementation (2022 to 2024) phases. The outcomes will be (1) suicide mortality, (2) hospitalizations for suicide attempts, and (3) emergency room visits for suicide attempts. Datasets covering September 2015 to August 2024 will be provided by public health organizations in both jurisdictions, that is, the Institut national de la santé publique du Québec and Santé publique France. In Quebec, control sites will consist of the 14 other health regions with a population of at least 50,000, while in France, control sites will include the 18 metropolitan areas with a status comparable to that of Brest Métropole. The analysis will focus on age- and sex-adjusted monthly rates of the specified outcomes, with an emphasis on changes across the study phases to assess the putative effectiveness of the CQFD-I intervention. We hypothesize that each study outcome will decrease by 20% at implementation sites compared to control sites between the preimplementation and postimplementation phases.
resultsThis project is funded by the Ministère de la Santé et des Services Sociaux du Québec, with access to data and expertise representing in-kind contributions from Santé publique France and Institut national de la santé publique du Québec. Data collection, led by the first author, will take place in September 2027 to allow for the delay required to confirm suicide deaths in official registers, with analysis planned between 2027 and 2028.
conclusionsTo our knowledge, this study will be the first to document the outcomes of a multimodal suicide prevention program targeting geographically defined areas within 2 countries, not limited to the European Union. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/66976.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.